Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.60 |
| ▸ | PDE4A | P27815 | 17/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4438899 | 1.00 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4CTP53 | |
| SCHEMBL2799859 | 1.00 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4CTP53 | |
| SCHEMBL4449911 | 0.90 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CVEGFA | |
| SCHEMBL2800202 | 0.90 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CVEGFA | |
| SCHEMBL2798274 | 0.90 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CVEGFA | |
| SCHEMBL2798368 | 0.89 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2799862 | 0.89 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2799802 | 0.88 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CVEGFA | |
| SCHEMBL2800215 | 0.88 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CVEGFA | |
| SCHEMBL2801940 | 0.87 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551805-B1 | SUBSTITUTED GAMMA-PHENYL-DELTA-LACTAMS AND USES RELATED THERETO | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-04-03 | — | — | EP | disclosed |
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137150-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110794-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | PDE4D 1120/4885PDE4A 696/4885PDE4B 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.